Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;32(2):154-161.
doi: 10.1053/j.akdh.2025.01.005.

Postdischarge Care of Acute Kidney Injury Survivors: An Opportunity for Targeted Nurse and Pharmacist Interventions

Affiliations
Review

Postdischarge Care of Acute Kidney Injury Survivors: An Opportunity for Targeted Nurse and Pharmacist Interventions

Melanie M Manis et al. Adv Kidney Dis Health. 2025 Mar.

Abstract

The incidence of acute kidney injury (AKI) is increasing, and with it, the population of individuals requiring post-AKI care. Postdischarge follow-up for AKI survivors is recommended within 90 days of an AKI episode to promote kidney recovery and potentially prevent progression of kidney disease. However, timely postdischarge care is often lacking or fragmented and poses a missed opportunity to prevent long-term complications of this condition. Suggested elements of follow-up care begin with a scheduled appointment with a physician and involve a bundled approach to care with health care providers' communicating across sites, remote patient monitoring devices, review of medications, education, access, kidney care evaluation, and interdisciplinary collaboration to achieve these patient care goals. This article provides an overview of guidance documents for post-AKI care and the roles of the nurse and pharmacist as part of an interdisciplinary team in postdischarge care after a patient incurs an episode of AKI.

Keywords: Acute kidney injury; Nurses; Pharmacists; Telemedicine; Transitional care.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure: L.F. serves on DSMB for Novonordisk and Regeneron. P.P. consults for Chiesi Pharmaceuticals (nothing in this space), AKICept (no products on market), and P.P. is an investigator in a Baxter citrate CRRT study. E.S. serves on the Editorial Board of CJASN and has received royalties as an author for UpToDate. J.A.N. is supported by grants from the National Institute of Diabetes and Digestive Kidney Diseases (R01DK128208, R01DK133539, and U54DK137307). F.P.W. has received support from AKI grants R01DK113191, P30DK079310, and R01HS027626. S.K.G. receives grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK121730), the National Center for Complementary and Integrative Health U54AT008909, and the Jewish Healthcare Foundation.

Similar articles

References

    1. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol. 2006;17(4):1143–1150. - PubMed
    1. Swaminathan M, Shaw AD, Phillips-Bute BG, et al. Trends in acute renal failure associated with coronary artery bypass graft surgery in the United States. Crit Care Med. 2007;35(10):2286–2291. - PubMed
    1. Silver SA, Siew ED. Follow-up care in acute kidney injury: lost in transition. Adv Chronic Kidney Dis. 2017;24(4):246–252. - PubMed
    1. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442–448. - PMC - PubMed
    1. Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE, Perkins RM. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int. 2012;81(5):477–485. - PubMed

LinkOut - more resources